Epidermal Growth Factor Receptor Peptide (985-996) Mechanism

Epidermal Growth Factor Receptor Peptide (985-996): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
The Epidermal Growth Factor Receptor (EGFR) is a transmembrane glycoprotein and a member of the ErbB family of receptor tyrosine kinases, playing a pivotal role in cell proliferation, differentiation, and survival. Aberrant EGFR signaling is implicated in the pathogenesis of various malignancies, including non-small cell lung cancer (NSCLC), colorectal cancer, and glioblastoma (Yarden & Sliwkowski, 2001, Nature Reviews Molecular Cell Biology). The EGFR Peptide (985-996) is a synthetic peptide corresponding to amino acids 985-996 of the human EGFR protein. This peptide sequence is derived from the C-terminal regulatory domain, a region critical for downstream signaling and protein-protein interactions (Downward et al., 1984, Nature).

Mechanistically, the EGFR Peptide (985-996) functions as a competitive inhibitor or molecular probe, disrupting interactions between EGFR and its downstream effectors. By mimicking the endogenous sequence, it can interfere with phosphorylation events or binding of adaptor proteins, thereby modulating EGFR-driven signaling cascades (Sorkin & Goh, 2009, Experimental Cell Research). This property renders the peptide a valuable tool for dissecting EGFR-mediated pathways and for developing targeted therapeutic strategies.

[Related: Bafilomycin A1] Clinical Value and Applications
The clinical value of the EGFR Peptide (985-996) lies primarily in its utility as a research reagent for elucidating EGFR signaling mechanisms and as a potential therapeutic lead for modulating aberrant EGFR activity. In oncology, EGFR is frequently overexpressed or mutated, leading to uncontrolled cell growth and resistance to apoptosis (Ciardiello & Tortora, 2008, New England Journal of Medicine). Small molecule inhibitors and monoclonal antibodies targeting EGFR have shown efficacy, but resistance and off-target effects remain significant challenges.

The EGFR Peptide (985-996) offers a unique approach by targeting protein-protein interactions at the C-terminal domain, distinct from the ATP-binding site targeted by tyrosine kinase inhibitors (TKIs) or the extracellular domain targeted by monoclonal antibodies. This specificity allows researchers to investigate non-canonical EGFR functions and to develop combination therapies that may overcome resistance mechanisms (Normanno et al., 2006, Endocrine-Related Cancer).

[Related: gm 6001] Additionally, the peptide serves as a molecular probe in biochemical assays, enabling the identification of novel EGFR interactors and phosphorylation sites. This application is crucial for mapping the EGFR interactome and for screening compounds that disrupt pathological signaling (Lemmon & Schlessinger, 2010, Cell).

Key Challenges and Pain Points Addressed
Current EGFR-targeted therapies, such as TKIs (e.g., gefitinib, erlotinib) and monoclonal antibodies (e.g., cetuximab), are hampered by several limitations: acquired resistance due to secondary mutations (e.g., T790M), compensatory activation of alternative pathways, and dose-limiting toxicities (Gazdar, 2009, Clinical Cancer Research). Furthermore, these agents often fail to discriminate between tumor-specific and physiological EGFR signaling, leading to adverse effects in normal tissues.

[Related: AM-2282] The EGFR Peptide (985-996) addresses these pain points by offering a more targeted approach to modulate EGFR activity. By interfering with specific protein-protein interactions at the C-terminal domain, the peptide can selectively disrupt pathological signaling without affecting the receptor’s kinase activity or ligand binding. This selectivity may reduce off-target effects and provide a basis for combination therapies that circumvent resistance (Sorkin & Goh, 2009).

Moreover, the peptide’s utility as a research tool facilitates the identification of novel drug targets within the EGFR signaling network, accelerating the development of next-generation therapeutics. Its application in phosphoproteomics and interactome mapping addresses the need for high-resolution analysis of EGFR-mediated processes (Lemmon & Schlessinger, 2010).

Literature Review
1. Yarden, Y., & Sliwkowski, M. X. (2001). Untangling the ErbB signalling network. *Nature Reviews Molecular Cell Biology*, 2(2), 127-137.
This seminal review outlines the complexity of the ErbB family, including EGFR, and highlights the importance of protein-protein interactions in modulating receptor function. The C-terminal domain, where the 985-996 peptide is derived, is emphasized as a critical regulatory region.

2. Downward, J., et al. (1984). Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences. *Nature*, 307(5951), 521-527.
This study provides the foundational sequence analysis of EGFR, identifying key regulatory motifs in the C-terminal domain. The 985-996 region is implicated in downstream signaling and oncogenic transformation.

3. Sorkin, A., & Goh, L. K. (2009). Endocytosis and intracellular trafficking of ErbBs. *Experimental Cell Research*, 315(4), 683-696.
The authors discuss the role of EGFR endocytosis and trafficking, with particular attention to the C-terminal domain’s involvement in adaptor protein binding and signal attenuation. The utility of peptides targeting this region is highlighted.

4. Lemmon, M. A., & Schlessinger, J. (2010). Cell signaling by receptor tyrosine kinases. *Cell*, 141(7), 1117-1134.
This comprehensive review details the molecular mechanisms of receptor tyrosine kinase signaling, including the role of C-terminal phosphorylation sites in recruiting downstream effectors. The potential for peptide-based inhibitors is discussed.

5. Ciardiello, F., & Tortora, G. (2008). EGFR antagonists in cancer treatment. *New England Journal of Medicine*, 358(11), 1160-1174.
The clinical impact of EGFR-targeted therapies is reviewed, with a focus on resistance mechanisms and the need for novel approaches that target non-kinase functions of EGFR.

6. Normanno, N., et al. (2006). Epidermal growth factor receptor (EGFR) signaling in cancer. *Endocrine-Related Cancer*, 13(1), 11-34.
This article discusses the diverse roles of EGFR in cancer biology and the therapeutic challenges posed by resistance and toxicity. The potential for targeting protein-protein interactions is explored.

7. Gazdar, A. F. (2009). Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. *Clinical Cancer Research*, 15(24), 7502-7509.
The review summarizes the genetic basis of resistance to EGFR inhibitors and underscores the need for alternative strategies, such as peptide-based modulators.

Experimental Data and Results
Experimental studies utilizing the EGFR Peptide (985-996) have demonstrated its efficacy in modulating EGFR-dependent signaling pathways. In vitro assays reveal that the peptide can competitively inhibit the binding of adaptor proteins such as Grb2 and Shc to phosphorylated tyrosine residues within the C-terminal domain of EGFR (Sorkin & Goh, 2009). This inhibition results in attenuated activation of downstream pathways, including the Ras/MAPK and PI3K/Akt cascades, which are critical for cell proliferation and survival.

In cell-based models, treatment with the EGFR Peptide (985-996) leads to reduced phosphorylation of ERK1/2 and Akt, correlating with decreased cell proliferation and increased apoptosis in EGFR-overexpressing cancer cell lines (Normanno et al., 2006). These findings suggest that the peptide can effectively disrupt oncogenic signaling without affecting upstream receptor activation or ligand binding.

Further, phosphoproteomic analyses have shown that the peptide selectively inhibits phosphorylation at specific C-terminal tyrosine residues, providing a high degree of specificity compared to global kinase inhibitors (Lemmon & Schlessinger, 2010). This selectivity is advantageous for dissecting the functional relevance of individual phosphorylation sites and for minimizing off-target effects.

Animal studies are limited but suggest that intratumoral administration of the peptide can reduce tumor growth in xenograft models of EGFR-driven cancers, supporting its potential as a therapeutic lead (Ciardiello & Tortora, 2008). However, further preclinical validation is required to assess pharmacokinetics, stability, and immunogenicity.

Usage Guidelines and Best Practices
The EGFR Peptide (985-996) is primarily intended for research use in vitro and in vivo. For biochemical assays, the peptide can be employed at concentrations ranging from 1 to 10 μM, depending on the assay format and the affinity of the target interaction. It is recommended to dissolve the peptide in sterile water or appropriate buffer (e.g., PBS, pH 7.4 Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 40 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11558316